Filing summary
Issuer mismatch: The request identifies Vyome Holdings, Inc., but the supplied Form 10-Q is for ReShape Lifesciences Inc. (Nasdaq: RSLS). This summary reflects the filing provided, not a Vyome filing. The report covers the quarter and six months ended June 30, 2023; financial amounts below are in millions of dollars unless stated otherwise.
Business context and reporting period
ReShape sells the Lap-Band adjustable gastric banding system and offers ReShapeCare and ReShape Marketplace. The Diabetes Bloc-Stim Neuromodulation device remains in development; the filing reports no revenue for it or the Obalon line. Lap-Band accounted for nearly all revenue and gross profit. The statements are unaudited.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $2.254 | $2.892 | $4.541 | $5.332 |
| Gross profit | $1.194 | $1.883 | $2.418 | $3.101 |
| Gross margin | 53.0% | 65.1% | 53.2% | 58.2% |
| Operating loss | $(3.976) | $(9.244) | $(9.608) | $(17.356) |
| Net loss | $(3.493) | $(9.444) | $(6.155) | $(17.559) |
| Net loss per share | $(1.08) | $(24.45) | $(2.48) | $(46.37) |
Q2 revenue fell 22.1% year over year, principally from lower U.S. and European sales. Six-month revenue fell 14.8%. Gross margin declined as lower sales left fixed overhead less absorbed. Operating expenses fell substantially, chiefly from reduced marketing and personnel costs and lower prior-year litigation expense. The six-month non-GAAP adjusted EBITDA loss was $9.075 million, versus $14.951 million in 2022; the filing cautions that this measure is not a substitute for GAAP results.
Cash flow: Net cash used in operations was $11.723 million in the first half, compared with $13.800 million a year earlier. Investing activities used $0.010 million. Financing provided $12.451 million, mainly from February and April 2023 offerings. Cash, cash equivalents and restricted cash ended at $4.667 million, up from $3.955 million at year-end 2022.
Balance sheet at June 30: Cash and cash equivalents were $4.567 million, restricted cash $0.100 million, receivables $1.975 million, and inventory $3.268 million. Current assets were $10.544 million and current liabilities $4.404 million, giving working capital of approximately $6.1 million. Total liabilities were $5.114 million and stockholders’ equity $6.738 million. The filing reports no conventional borrowing balance; it records a $0.512 million warrant liability. Common shares outstanding were 3,452,169 at quarter-end and 3,452,447 as of August 3, 2023.
Material changes and unusual items
- Common shares outstanding increased from 519,219 at December 31, 2022, primarily through equity offerings and warrant exercises; the company also completed a 1-for-50 reverse stock split in December 2022.
- February and April offerings generated approximately $12.7 million in gross proceeds combined. The April financing included common shares and pre-funded and other warrants. Warrant terms and exercises affected share counts and earnings.
- A $3.438 million first-half gain from changes in fair value of liability warrants reduced reported net loss; this is a noncash, valuation-sensitive item.
- A New York court entered judgment for Cowen in May 2023. ReShape paid the $1.35 million judgment plus interest and the first $0.275 million attorney-fee installment; $0.400 million of remaining fees was accrued at June 30.
- The company moved its principal offices to Irvine, California, under a 36-month lease commencing May 1, 2023.
Outlook, risks and controls
Management said it expects revenue growth in the second half of 2023 as targeted digital marketing, efforts to increase Lap-Band demand, and new calibration-tube sizes take effect. This is management’s expectation, not a quantified forecast or assurance. Planned initiatives include developing DBSN, expanding Lap-Band sales, and introducing or extending ReShapeCare and ReShape Marketplace.
The filing states that revenue is insufficient to cover operating costs and that available cash may not fund current operations for more than twelve months from the filing date. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern; its plans do not alleviate that doubt. Additional financing may be needed, with no assurance it will be available on acceptable terms. Spending reductions, including in marketing and product development, may be necessary.
Management reported that internal control over financial reporting was not effective at June 30, 2023, citing material weaknesses involving accounting resources and controls, purchase accounting, income taxes, journal-entry approval and IT access/change management. Remediation was underway. The company also disclosed ongoing exposure to product-liability and other industry litigation, although it reported no other known material pending or threatened litigation. It said there were no material changes to the risk factors in its 2022 Form 10-K.
Important facts for investors to verify
- Confirm issuer and ticker: the supplied filing is ReShape Lifesciences Inc. (RSLS), not Vyome Holdings, Inc.
- Assess cash runway against operating cash use, and whether additional financing will be required and available.
- Track revenue trends, gross margin, and whether management’s anticipated second-half 2023 growth materialized.
- Review potential dilution and warrant terms, exercises, and fair-value effects on reported earnings.
- Monitor remediation of the disclosed material weaknesses and the remaining Cowen attorney-fee payments.